Welcome to the brave new world of psychedelic wellness and investors are taking notice. Mushroom penny stocks have witnessed the cannabis craze the last 5 years or so and are feverishly hoping the mushroom craze is next to bring their portfolios lots of GREEN.
After decades underground, hallucinogens such as ketamine, LSD, psilocybin, and MDMA are getting a fresh look from the medical establishment, thanks to myriad studies suggesting silver bullet–like efficacy in the treatment of anxiety, depression, and addiction, among other ailments. MDMA, renowned for its bliss-inducing effect—hence the street name “ecstasy”—is on course to be approved for the treatment of post-traumatic stress disorder (PTSD) within the next year or two.
Synthetic forms of psilocybin, the active compound in magic mushrooms, were given “breakthrough” designation by the FDA in 2018, allowing for fast-tracking of drug trials. Meanwhile, this past November, Oregon became the first state in the nation to legalize psilocybin for medical use, an advance not lost on the investors flocking to start-ups like MindMed and Compass Pathways, both of which are developing psilocybin treatments in anticipation of a cannabis-style psychedelics boom. A mental-health revolution is at hand—and it’s long overdue.
Friday’s news that AIkido Pharma Inc. (NASDAQ: AIKI) closed on a $75 million dollar offering further confirms the investment community’s appetite for magic mushroom stocks and the need for additional research and development. AIkido Pharma recently entered into Letter Of Intent with Silo Pharma for the use of psilocybin and peptide therapy for cancer treatment. Before we list 8 penny stocks associated with the “mushroom craze”, lets learn more about its effects, dosing, where it’s legal what psilocybin is.
